- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Dr Mostafa Analoui, PHD, Senior Director at Pfizer Global Research and Development is confirmed to speak on critical needs in clinical diagnostics and key challenges in drug discovery and development at Biopharmaceutical Nanotechnology http://www.iqpc.com/uk/nanotech/nnow in London, UK on 31st March - 1st April 2008.
Research and Development in Life Sciences are greatly impacted by recent advances in conventional and emerging technologies, especially in understanding of disease, drug discovery, and novel diagnostics. These technological contributions have led to innovation and introduction of a number of therapeutic solutions with notable improvement in public health. Nanobiotechnology, a basket of wide ranging technologies, is being positioned as one of critical class of technologies, with broad reaching impacts in Life Science R&D, including drug discovery, formulation, delivery, clinical assessment and monitoring.
Nanobiotechnology's impact within drug discovery and development is manifesting itself in two ways, with different time horizons. The immediate and short term impact is being materialized through innovative formulation and delivery of compounds in different stages of development, including the ones already in the market. In the longer term horizon, there is a promise of new class of drugs designed around nanobiotechnology approach from ground up. There are early indicators of such potential success stories worth allocating resources and attention.
Dr Mostafa Analoui's presentation at the Biopharmaceutical Nanotechnology conference in London, UK will discuss some of the areas that nanobiotechnology could play through enhancement in current paradigm, as well as new directions in drug development, using examples of current utility of nanotechnology, as well as ongoing research areas. Dr Analoui will also provide delegates with a snapshot of global business and investment environment around nanobiotechnology, including current and projected level of private and government investments, trends in IP ownership, as well as fundamental questions around assessment of investment strategies and risks.
As well as being a Senior Director at Pfizer Global Research and Development in Connecticut Dr Analoui is also adjunct Professor of Radiology and Oral Pathology, Medicine at Indiana University Schools of Medicine and Dentistry. Dr Analoui is actively involved in management and scientific/business development of novel biotechnologies and methodologies, global strategies and education. Dr Analoui was previously the Director of Oral and Maxillofacial Imaging Research at Indiana University, and Associate professor of Biomedical Engineering and Electrical & Comp Engineering at Purdue University. He was also President and CEO of Therametric Technology Inc.
In addition to industry leadership in biomedical filed, he lectures nationally and internationally. He has also served on various scientific and business advisory committees and boards. Dr. Analoui has authored over 130 publications, including journal articles, book chapters, and technical reports.
About Biopharmaceutical Nanotechnology 2008
The use of Nanotechnology in the discovery and development of biopharmaceuticals is a major breakthrough, with the potential to revolutionise and enhance your ability to develop new and innovative products.
Biopharmaceutical Nanotechnology is the first industry-led event in Europe focussing on drug discovery, drug delivery and particular therapeutic areas. Join global experts for a practical, commercially applicable perspective on how to:
Stay competitive by applying the experience of key industry players who have used nanotechnology in the administration of drugs
Discover how nanotechnology combines drugs and devices to increase your product efficiency
Learn the best ways to implement drug discovery techniques into your business processes
Discuss how to employ latest therapeutic developments into your product pipeline
For further information, visit http://www.iqpc.com/uk/nanotech/nnow
For more information, please click here
Copyright © Biopharmaceutical Nanotechnology 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Next-gen steel under the microscope March 18th, 2017
UC researchers use gold coating to control luminescence of nanowires: University of Cincinnati physicists manipulate nanowire semiconductors in pursuit of making electronics smaller, faster and cheaper March 17th, 2017
Harris & Harris Group Issues Its Financial Statements as of December 31, 2016, Posts Its Annual Shareholder Letter, And Will Host a Conference Call for Shareholders on Friday, March 17, 2017 March 15th, 2017
Rice's Tour to testify before Congress Wednesday March 14th, 2017